Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Opportunities to Optimize Cancer Policies Panel Discussion

Peter Clark, MA, MD, FRCP: A Payer Perspective

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Advertisement

Advertisement




Mar
21
Today In Oncology
FDA Approves Chemoimmunotherapy Regimen for Hodgkin Lymphoma
Hypofractionated Locoregional RT in Early Breast Cancer
Melanoma-Specific Survival With Sentinel Lymph Node Biopsy
Breast Cancer Ultrasensitive ctDNA Assay Findings and Outcomes After Neoadjuvant Therapy
AMA Survey Finds Rapid Growth in Physician AI Adoption
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo